UC-MSC therapy is currently being explored as a potential first-of-its-kind treatment for autism spectrum disorder, or ASD. Autism is a complex neurodevelopmental disorder, and no two children with autism are alike. Currently, the principal intervention for children with autism remains behavioral therapy, education, speech therapy, occupational therapy and symptom-based medical care.
Researchers are studying UC-MSCs as those cells might help modulate inflammation and immune activity in the body. Other scientists believe these pathways may be involved in some subgroups of children with autism. However, this is still under investigation. UC-MSC therapy is not a standard treatment for autism, and further studies are still required.
Why Are UC-MSCs Being Studied in Autism?
Mesenchymal stromal cells are spelled UC-MSCs. These cells are being investigated because they may secrete beneficial signals that influence the body’s immune system and tissue environment.
The point is not that these cells “repair” the brain directly. Instead, researchers are exploring whether UC-MSCs can help to dampen harmful inflammation or promote healthier signaling in the body. And it is why they are being investigated in autism research.
That said, caution is necessary. Having a scientific reason to study something doesn’t imply that it has already been demonstrated to work.
What Do Current Safety Studies Show?
Safety is a major concern regarding UC-MSC therapy for autism. Early studies suggest that infusion could be possible and generally manageable at research sites, but that does not mean the treatment is yet fully proven or without risks.
In a preliminary phase, cord tissue-derived MSCs were delivered in an intravenous infusion that was found to be feasible and generally well tolerated in children with autism. A few children had immune related changes such as anti-HLA antibodies but no concerning immediate safety issue was noted. That means short-term safety may appear to be satisfactory in some studies, but close observation is still crucial.
Previous studies also reported mostly manageable short-term side effects, but many of them had shortcomings. Some were open-label, others small; some used mixed products instead of UC-MSCs exclusively. As a result, safety findings should still be considered cautiously.
What Outcomes Have Been Reported?
Some studies showed benefits in behavior, communication, or clinical rating scores following treatment. That’s one reason the subject has drawn attention. But these results should be interpreted cautiously. Many of the earlier studies were small and lacked a robust trial design. Some were not randomized. Some were open-label, meaning families and researchers knew the child was receiving treatment. This can complicate whether the treatment itself caused the improvement.
So here is the best way to summarize current evidence: early studies have shown promise, but not enough that we can call UC-MSC therapy an established treatment for autism.
Is There a Standard Dose?
It is one of the most FAQs but the answer to it, unfortunately, remains that there is no “standard” UC-MSC dose for autism yet. Different treatment protocols have been used in different studies. In the Duke phase I study, children were given 2 × 10^6 cells per kilogram per intravenous; treatments were administered at intervals. The latter of these two dose levels (6 × 10^6 cells/kg) was utilized in the Duke phase II study design.
These numbers are informative for doing research, not something to be presented as the official standard doses. They remain investigational doses in clinical trials.
This means the question of dosage is still being studied, and in autism, researchers haven’t agreed on one best dose.
What Is the Most Balanced Conclusion?
In the end, the most honest conclusion is that UC-MSC therapy for autism is a domain of genuine scientific interest, but ripe new and epicene, neither proved nor unproved.
What’s still uncertain: Researchers are racing to answer key questions like:
- which patients may benefit most
- what dose is best
- how frequently treatment needs to be provided
- what outcomes should be measured
- how safe the treatment is over a longer period of time
Overall, early studies indicate that UC-MSC therapy is worth exploring further. But for the time being, it can be characterized as an investigational therapy not a convention treatment for autism.